title: Dantrolene, a treatment for Alzheimer disease?
abstract: Alzheimer disease (AD) is a fatal progressive disease and the most common form of dementia without effective treatments. Previous studies support that the disruption of endoplasmic reticulum Ca through overactivation of ryanodine receptors plays an important role in the pathogenesis of AD. Normalization of intracellular Ca homeostasis could be an effective strategy for AD therapies. Dantrolene, an antagonist of ryanodine receptors and an FDA-approved drug for clinical treatment of malignant hyperthermia and muscle spasms, exhibits neuroprotective effects in multiple models of neurodegenerative disorders. Recent preclinical studies consistently support the therapeutic effects of dantrolene in various types of AD animal models and were summarized in the current review.
authors.affiliation: *Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA †Department of Medicinal Chemistry, School of Pharmacy, The Fourth Military Medical School, Xi'an, Shaanxi, China.
authors.forename: Li
authors.initials: L
authors.lastname: Liang
authors.forename: Huafeng
authors.initials: H
authors.lastname: Wei
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism*; D000818:Animals; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology; D003620:Dantrolene / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019837:Ryanodine Receptor Calcium Release Channel / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D018696:Neuroprotective Agents; D019837:Ryanodine Receptor Calcium Release Channel; D003620:Dantrolene